Advertisement
Singapore markets close in 5 hours 40 minutes
  • Straits Times Index

    3,323.15
    -3.13 (-0.09%)
     
  • Nikkei

    39,726.39
    +553.24 (+1.41%)
     
  • Hang Seng

    18,046.28
    -26.62 (-0.15%)
     
  • FTSE 100

    8,247.79
    -33.76 (-0.41%)
     
  • Bitcoin USD

    62,009.14
    +794.51 (+1.30%)
     
  • CMC Crypto 200

    1,286.60
    +37.48 (+3.00%)
     
  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     
  • Dow

    39,112.16
    -299.05 (-0.76%)
     
  • Nasdaq

    17,717.65
    +220.84 (+1.26%)
     
  • Gold

    2,329.90
    -0.90 (-0.04%)
     
  • Crude Oil

    81.15
    +0.32 (+0.40%)
     
  • 10-Yr Bond

    4.2380
    -0.0100 (-0.24%)
     
  • FTSE Bursa Malaysia

    1,587.85
    +2.47 (+0.16%)
     
  • Jakarta Composite Index

    6,931.04
    +48.34 (+0.70%)
     
  • PSE Index

    6,285.39
    -13.66 (-0.22%)
     

Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Chimerix, Inc.
Chimerix, Inc.

DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET.

An audio webcast of the panel discussion will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

CONTACT:

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com